AIBP therapy

AIBP治疗

基本信息

  • 批准号:
    10551912
  • 负责人:
  • 金额:
    $ 93万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2017
  • 资助国家:
    美国
  • 起止时间:
    2017-02-01 至 2024-01-31
  • 项目状态:
    已结题

项目摘要

Project Summary This proposal describes a research program to establish mechanistic foundations and conduct preclinical studies toward AIBP therapy. We discovered that the secreted apoA-I binding protein (AIBP) accelerates cholesterol efflux from endothelial cells (EC) and macrophages and targets HDL to TLR4-occupied lipid rafts. Resulting targeted cholesterol removal from the plasma membrane and reduction of lipid rafts leads to reduced TLR4-mediated inflammatory responses. The significance of this discovery is in the widespread character of the AIBP/lipid rafts mechanism of anti-inflammatory regulation, which can be relevant to many inflammatory conditions. The translational importance of our findings arises from the extracellular mode of AIBP regulation and thus the possibility of recombinant protein infusion or inhalation. Considering an atheroprotective function of AIBP, the integrity and the normal physiological function of EC are critically important for maintaining a healthy vascular wall. We have strong preliminary data showing that AIBP facilitates HDL-mediated cholesterol efflux from EC, reduces EC expression of inflammatory genes and reduces monocyte adhesion to EC. These results suggest a strong impetus to pursue AIBP atheroprotective therapeutic applications. Cardiac reperfusion after an acute myocardial infarction (MI), or ischemia/reperfusion (I/R), contributes to myocardial injury, which generates subsequent inflammatory cascade, which in turn perpetuates cardiac damage. Innate immune receptors in general and TLR4 in particular critically contribute to I/R damage. Reducing inflammatory responses to I/R via increased removal of cholesterol from cardiomyocytes and vascular cells will be particularly important for post-MI patients. We posit that infusions of AIBP, alone or in combination with reconstituted HDL, will provide benefit to post-MI patients' health because AIBP specifically targets HDL to inflammatory cells. The extracellular mechanism of AIBP action also opens the possibility of its local administration in lung inflammation. Acute respiratory distress syndrome (ARDS) often results in death of those afflicted by its most severe subset due to the lack of effective therapies. Excessive inflammatory responses, including recruitment of neutrophils, secretion of cytokines and the development of alveolar edema, characterize ARDS in humans and rodents. We have shown in a mouse model of ARDS that nebulized AIBP significantly reduces lung inflammation. Our research program will focus on understanding basic anti- inflammatory mechanisms of AIBP and will use preclinical animal models, including mouse and zebrafish, and patients' blood samples to evaluate the potential of AIBP therapy in atheroprotection and in treatment of post- MI and ARDS patients.
项目摘要 该提案描述了一项研究计划,以建立机制基础并进行临床前研究。 AIBP治疗的研究。我们发现分泌的apoA-I结合蛋白(AIBP)加速了 胆固醇从内皮细胞(EC)和巨噬细胞流出,并将HDL靶向TLR 4占据的脂筏。 由此产生的靶向胆固醇从质膜去除和脂筏减少导致降低的 TLR 4介导的炎症反应。这一发现的意义在于, AIBP/脂筏机制的抗炎调节,这可能与许多炎症 条件我们的研究结果的翻译重要性来自AIBP调节的细胞外模式 从而增加了重组蛋白输注或吸入的可能性。考虑到动脉粥样硬化保护功能 因此,EC的完整性和正常的生理功能对于维持AIBP的功能至关重要。 健康血管壁。我们有强有力的初步数据表明,AIBP促进HDL介导的胆固醇 从EC流出,减少炎性基因的EC表达,并减少单核细胞粘附EC。这些 结果显示了追求AIBP动脉粥样硬化保护治疗应用的强大动力。心脏再灌注 急性心肌梗死(MI)或缺血/再灌注(I/R)后,导致心肌损伤, 产生随后的炎症级联反应,这反过来又使心脏损伤永久化。先天免疫 受体,特别是TLR 4,对I/R损伤起关键作用。减少炎症 通过增加从心肌细胞和血管细胞中清除胆固醇对I/R的反应, 对心肌梗死后患者尤为重要。我们认为AIBP单独或与 重组HDL将为MI后患者的健康提供益处,因为AIBP特别针对HDL, 炎症细胞AIBP作用的细胞外机制也开启了其局部作用的可能性。 给药在肺部炎症。急性呼吸窘迫综合征(ARDS)常导致患者死亡, 由于缺乏有效的治疗方法,他们受到最严重的亚群的折磨。过度的炎症反应, 包括中性粒细胞的募集、细胞因子的分泌和肺泡水肿的发展, 描述人类和啮齿类动物的ARDS。我们已经在小鼠ARDS模型中显示雾化AIBP 显著降低肺部炎症。我们的研究计划将侧重于了解基本的反- AIBP的炎症机制,并将使用临床前动物模型,包括小鼠和斑马鱼, 患者的血液样本,以评估AIBP治疗在动脉粥样硬化保护和治疗后 MI和ARDS患者。

项目成果

期刊论文数量(11)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Context-Dependent Role of Oxidized Lipids and Lipoproteins in Inflammation.
氧化脂质和脂蛋白在炎症中的上下文依赖性作用。
Lipoprotein lipase regulates hematopoietic stem progenitor cell maintenance through DHA supply.
  • DOI:
    10.1038/s41467-018-03775-y
  • 发表时间:
    2018-04-03
  • 期刊:
  • 影响因子:
    16.6
  • 作者:
    Liu C;Han T;Stachura DL;Wang H;Vaisman BL;Kim J;Klemke RL;Remaley AT;Rana TM;Traver D;Miller YI
  • 通讯作者:
    Miller YI
From Inert Storage to Biological Activity-In Search of Identity for Oxidized Cholesteryl Esters.
  • DOI:
    10.3389/fendo.2020.602252
  • 发表时间:
    2020
  • 期刊:
  • 影响因子:
    5.2
  • 作者:
    Gonen A;Miller YI
  • 通讯作者:
    Miller YI
Palmitate and minimally-modified low-density lipoprotein cooperatively promote inflammatory responses in macrophages.
  • DOI:
    10.1371/journal.pone.0193649
  • 发表时间:
    2018
  • 期刊:
  • 影响因子:
    3.7
  • 作者:
    Ann SJ;Kim KK;Cheon EJ;Noh HM;Hwang I;Yu JW;Park S;Kang SM;Manabe I;Miller YI;Kim S;Lee SH
  • 通讯作者:
    Lee SH
Biology of Lipid Rafts: Introduction to the Thematic Review Series.
脂筏生物学:专题评论系列简介。
  • DOI:
    10.1194/jlr.in119000330
  • 发表时间:
    2020
  • 期刊:
  • 影响因子:
    6.5
  • 作者:
    Sviridov,Dmitri;Miller,YuryI
  • 通讯作者:
    Miller,YuryI
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Yury Miller其他文献

Yury Miller的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Yury Miller', 18)}}的其他基金

AIBP and regulation of neuropathic pain
AIBP 和神经性疼痛的调节
  • 批准号:
    9816541
  • 财政年份:
    2019
  • 资助金额:
    $ 93万
  • 项目类别:
Reversal of preexisting neuropathic pain by spinal delivery of AIBP
通过脊髓输送 AIBP 逆转先前存在的神经性疼痛
  • 批准号:
    9750836
  • 财政年份:
    2018
  • 资助金额:
    $ 93万
  • 项目类别:
Reversal of preexisting neuropathic pain by spinal delivery of AIBP
通过脊髓输送 AIBP 逆转先前存在的神经性疼痛
  • 批准号:
    10197482
  • 财政年份:
    2018
  • 资助金额:
    $ 93万
  • 项目类别:
Cholesterol Regulation of Inflammatory Macrophages in Atherosclerosis
动脉粥样硬化中炎症巨噬细胞的胆固醇调节
  • 批准号:
    10188606
  • 财政年份:
    2017
  • 资助金额:
    $ 93万
  • 项目类别:
AIBP therapy
AIBP治疗
  • 批准号:
    9240927
  • 财政年份:
    2017
  • 资助金额:
    $ 93万
  • 项目类别:
AIBP therapy
AIBP治疗
  • 批准号:
    10331313
  • 财政年份:
    2017
  • 资助金额:
    $ 93万
  • 项目类别:
Project 2: Cholesterol Regulation of Inflammatory Macrophages in Atherosclerosis
项目2:动脉粥样硬化中炎症巨噬细胞的胆固醇调节
  • 批准号:
    10334095
  • 财政年份:
    2017
  • 资助金额:
    $ 93万
  • 项目类别:
AIBP and Endothelial Function
AIBP 和内皮功能
  • 批准号:
    8885205
  • 财政年份:
    2015
  • 资助金额:
    $ 93万
  • 项目类别:
AIBP and Endothelial Function
AIBP 和内皮功能
  • 批准号:
    9039657
  • 财政年份:
    2015
  • 资助金额:
    $ 93万
  • 项目类别:
Early Forms of Oxidized LDL, TLRs and Atherosclerosis
氧化 LDL、TLR 和动脉粥样硬化的早期形式
  • 批准号:
    7839765
  • 财政年份:
    2009
  • 资助金额:
    $ 93万
  • 项目类别:

相似海外基金

Combining Mechanistic Modelling with Machine Learning for Diagnosis of Acute Respiratory Distress Syndrome
机械建模与机器学习相结合诊断急性呼吸窘迫综合征
  • 批准号:
    EP/Y003527/1
  • 财政年份:
    2024
  • 资助金额:
    $ 93万
  • 项目类别:
    Research Grant
The Association Between Aging, Inflammation, and Clinical Outcomes in Acute Respiratory Distress Syndrome
衰老、炎症与急性呼吸窘迫综合征临床结果之间的关联
  • 批准号:
    10722669
  • 财政年份:
    2023
  • 资助金额:
    $ 93万
  • 项目类别:
Sedatives Pharmacology in Acute Respiratory Distress Syndrome- SPA
急性呼吸窘迫综合征中的镇静药理学 - SPA
  • 批准号:
    491387
  • 财政年份:
    2023
  • 资助金额:
    $ 93万
  • 项目类别:
    Fellowship Programs
New mechanism-based TREM-1 therapy for acute respiratory distress syndrome
基于新机制的 TREM-1 疗法治疗急性呼吸窘迫综合征
  • 批准号:
    10678788
  • 财政年份:
    2023
  • 资助金额:
    $ 93万
  • 项目类别:
Great Lakes Clinical Center of the Acute Respiratory Distress Syndrome, Pneumonia and Sepsis (APS) Consortium
急性呼吸窘迫综合征、肺炎和败血症 (APS) 联盟五大湖临床中心
  • 批准号:
    10646578
  • 财政年份:
    2023
  • 资助金额:
    $ 93万
  • 项目类别:
Effect of ADAMTS13 on pathogenesis of acute respiratory distress syndrome
ADAMTS13 对急性呼吸窘迫综合征发病机制的影响
  • 批准号:
    23K08447
  • 财政年份:
    2023
  • 资助金额:
    $ 93万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
A Novel Synthetic Biology-Derived Microbiome Therapeutic to Treat Viral-Induced Acute Respiratory Distress Syndrome (ARDS)
一种新型合成生物学衍生的微生物疗法,可治疗病毒引起的急性呼吸窘迫综合征(ARDS)
  • 批准号:
    10601865
  • 财政年份:
    2023
  • 资助金额:
    $ 93万
  • 项目类别:
Development of drug therapy targeting ferroptosis, iron-dependent cell death for acute respiratory distress syndrome.
开发针对铁死亡(急性呼吸窘迫综合征的铁依赖性细胞死亡)的药物疗法。
  • 批准号:
    23K08360
  • 财政年份:
    2023
  • 资助金额:
    $ 93万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Sustainable Implementation of Prone Positioning for the Acute Respiratory Distress Syndrome
持续实施俯卧位治疗急性呼吸窘迫综合征
  • 批准号:
    10722194
  • 财政年份:
    2023
  • 资助金额:
    $ 93万
  • 项目类别:
Point-of-care system to assess the risk of trauma-induced acute respiratory distress syndrome
用于评估创伤引起的急性呼吸窘迫综合征风险的护理点系统
  • 批准号:
    10594793
  • 财政年份:
    2023
  • 资助金额:
    $ 93万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了